Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 | P14416 | 5/20 | 0.54 |
| ▸ | HTR2A | P28223 | 5/20 | 0.54 |
| ▸ | ACHE | P22303 | 6/20 | 0.46 |
| ▸ | BCHE | P06276 | 5/20 | 0.46 |
| ▸ | GRIN1 | Q05586 | 5/20 | 0.46 |
| ▸ | GRIN2A | Q12879 | 5/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.43 |
| ▸ | NPC1 | O15118 | 2/20 | 0.43 |
| ▸ | HPGD | P15428 | 2/20 | 0.43 |
| ▸ | RAB9A | P51151 | 2/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.43 |
| ▸ | POLB | P06746 | 2/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | TP53 | P04637 | 1/20 | 0.43 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.43 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.43 |
| ▸ | SOS1 | Q07889 | 1/20 | 0.42 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 2/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31297518 | 1.00 | DRD2 (0.54) | DRD2HTR2AACHEBCHEGRIN1 | |
| SCHEMBL7332801 | 0.98 | DRD2 (0.52) | DRD2HTR2AACHEBCHEGRIN1 | |
| SCHEMBL7327037 | 0.83 | BCHE (0.46) | ACHEBCHEGRIN1GRIN2AKDM4E | |
| SCHEMBL7335644 | 0.82 | ACHE (0.47) | DRD2HTR2AACHEBCHEGRIN1 | |
| SCHEMBL28151329 | 0.78 | MAPT (0.52) | DRD2HTR2AACHEBCHEGRIN1 | |
| SCHEMBL10286364 | 0.75 | DRD2 (0.41) | DRD2HTR2AACHEKDM4ENPC1 | |
| SCHEMBL16872138 | 0.75 | ACHE (0.36) | ACHEBCHEGRIN1GRIN2AKDM4E | |
| SCHEMBL7333643 | 0.74 | DRD2 (0.75) | DRD2HTR2AKDM4ENPC1HPGD | |
| SCHEMBL9558713 | 0.74 | HTR2A (0.46) | DRD2HTR2AACHEBCHEGRIN1 | |
| SCHEMBL16872279 | 0.74 | KDM4E (0.49) | ACHEKDM4EALDH1A1MAPK1TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3939954-B1 | METHOD FOR INTRODUCING DEUTERATED LOWER ALKYL INTO AMINE MOIETY OF COMPOUND CONTAINING SECONDARY AMINE | OTSUKA PHARMA CO LTD (JP) | 2025-07-23 | — | — | EP | disclosed |
| US-20220127206-A1 | METHOD FOR INTRODUCING DEUTERATED LOWER ALKYL INTO AMINE MOIETY OF COMPOUND CONTAINING SECONDARY AMINE | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2022-04-28 | — | — | US | disclosed |
| EP-3939954-A1 | METHOD FOR INTRODUCING DEUTERATED LOWER ALKYL INTO AMINE MOIETY OF COMPOUND CONTAINING SECONDARY AMINE | Otsuka Pharmaceutical Co., Ltd. (JP) | 2022-01-19 | — | — | EP | disclosed |
| EP-3939954-A1 | METHOD FOR INTRODUCING DEUTERATED LOWER ALKYL INTO AMINE MOIETY OF COMPOUND CONTAINING SECONDARY AMINE | Otsuka Pharmaceutical Co., Ltd. (JP) | 2022-01-19 | — | — | EP | disclosed |
| CN-113518771-A | Method for introducing deuterated lower alkyl into amine part of compound containing secondary amine | 大塚制药株式会社 | 2021-10-19 | — | — | CN | disclosed |
| EP-0385237-B1 | 2-(1-piperazinyl)-4-phenylcycloalkanopyridine derivatives, processes for the production thereof, and pharmaceutical composition containing the same | DAINIPPON PHARMACEUTICAL CO (JP) | 1994-06-29 | — | — | EP | disclosed |
| US-5021421-A | Psychotropic agents | DAINIPPON PHARMACEUTICAL CO., LTD. (JP) | 1991-06-04 | — | — | US | disclosed |
| EP-0385237-A2 | 2-(1-piperazinyl)-4-phenylcycloalkanopyridine derivatives, processes for the production thereof, and pharmaceutical composition containing the same | DAINIPPON PHARMACEUTICAL CO., LTD. (JP) | 1990-09-05 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220127206-A1 | METHOD FOR INTRODUCING DEUTERATED LOWER ALKYL INTO AMINE MOIETY OF COMPOUND CONTAINING SECONDARY AMINE | MGMT, FANCD2, ADAR | DRD2 35/4885HTR2A 1004/4885ACHE 602/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.